SG11201704370XA - Low dosage a2a antagonist for the treatment of adhd and parkinsons - Google Patents

Low dosage a2a antagonist for the treatment of adhd and parkinsons

Info

Publication number
SG11201704370XA
SG11201704370XA SG11201704370XA SG11201704370XA SG11201704370XA SG 11201704370X A SG11201704370X A SG 11201704370XA SG 11201704370X A SG11201704370X A SG 11201704370XA SG 11201704370X A SG11201704370X A SG 11201704370XA SG 11201704370X A SG11201704370X A SG 11201704370XA
Authority
SG
Singapore
Prior art keywords
parkinsons
adhd
antagonist
treatment
low dosage
Prior art date
Application number
SG11201704370XA
Other languages
English (en)
Inventor
Lone Frydelund Larsen
Johan Areberg
Nathalie Breysse
Gamini Chandrasena
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of SG11201704370XA publication Critical patent/SG11201704370XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
SG11201704370XA 2014-12-03 2015-12-01 Low dosage a2a antagonist for the treatment of adhd and parkinsons SG11201704370XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201400704 2014-12-03
PCT/EP2015/078181 WO2016087429A1 (en) 2014-12-03 2015-12-01 Low dosage a2a antagonist for the treatment of adhd and parkinsons

Publications (1)

Publication Number Publication Date
SG11201704370XA true SG11201704370XA (en) 2017-06-29

Family

ID=58731664

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201704370XA SG11201704370XA (en) 2014-12-03 2015-12-01 Low dosage a2a antagonist for the treatment of adhd and parkinsons

Country Status (25)

Country Link
US (2) US20160158211A1 (ru)
EP (1) EP3226863A1 (ru)
JP (1) JP2017536400A (ru)
KR (1) KR20170090430A (ru)
CN (1) CN106999480A (ru)
AU (1) AU2015357197A1 (ru)
BR (1) BR112017011777A2 (ru)
CA (1) CA2966582A1 (ru)
CL (1) CL2017001407A1 (ru)
CO (1) CO2017004785A2 (ru)
CR (1) CR20170221A (ru)
DO (1) DOP2017000121A (ru)
EA (1) EA201790973A1 (ru)
EC (1) ECSP17030050A (ru)
IL (1) IL252355A0 (ru)
MA (1) MA41090A (ru)
MX (1) MX2017007027A (ru)
NI (1) NI201700066A (ru)
PE (1) PE20170926A1 (ru)
PH (1) PH12017500923A1 (ru)
SG (1) SG11201704370XA (ru)
SV (1) SV2017005441A (ru)
TN (1) TN2017000174A1 (ru)
TW (1) TW201632186A (ru)
WO (1) WO2016087429A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113166153A (zh) 2018-07-05 2021-07-23 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
CA3126735A1 (en) 2019-01-11 2020-07-16 Omeros Corporation Methods and compositions for treating cancer
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CN114917350B (zh) * 2022-06-21 2023-06-13 重庆医科大学附属第二医院 Cftr增强剂在注意缺陷与多动障碍中的应用及产品

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1700856T3 (en) * 2003-12-26 2015-12-14 Kyowa Hakko Kirin Co Ltd thiazole
EP2564871B1 (en) * 2008-07-23 2017-11-15 Kyowa Hakko Kirin Co., Ltd. Therapeutic Agent for Migraine
TWI548411B (zh) * 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
UA110097C2 (uk) * 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою
UA113383C2 (xx) * 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів

Also Published As

Publication number Publication date
TW201632186A (zh) 2016-09-16
CO2017004785A2 (es) 2017-08-31
DOP2017000121A (es) 2017-07-15
CA2966582A1 (en) 2016-06-09
TN2017000174A1 (en) 2018-10-19
IL252355A0 (en) 2017-07-31
EP3226863A1 (en) 2017-10-11
US20160158211A1 (en) 2016-06-09
PE20170926A1 (es) 2017-07-13
CL2017001407A1 (es) 2018-01-05
KR20170090430A (ko) 2017-08-07
JP2017536400A (ja) 2017-12-07
BR112017011777A2 (pt) 2018-02-20
MX2017007027A (es) 2017-08-24
CR20170221A (es) 2017-10-05
WO2016087429A1 (en) 2016-06-09
AU2015357197A1 (en) 2017-05-25
NI201700066A (es) 2018-01-04
SV2017005441A (es) 2017-08-25
US20180125835A1 (en) 2018-05-10
EA201790973A1 (ru) 2017-10-31
ECSP17030050A (es) 2017-08-31
CN106999480A (zh) 2017-08-01
PH12017500923A1 (en) 2017-11-20
MA41090A (fr) 2017-10-10

Similar Documents

Publication Publication Date Title
IL258931A (en) Medicinal compounds and methods
HK1257955A1 (zh) 用於治療肌聯蛋白類肌病和其他肌聯蛋白病變的材料和方法
HK1247614A1 (zh) 治療化合物及其用途
HK1243073A1 (zh) 治療性化合物及其用途
HK1249103B (zh) 多環氨甲醯基吡啶酮化合物及其藥物用途
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
HK1244000B (zh) 多環氨基甲酰吡啶酮化合物及其藥物用途
HK1253049A1 (zh) 糖基相互作用化合物及其使用方法
GB201403093D0 (en) Therapeutic compounds and their use
GB201413355D0 (en) Compositons and methods
GB201404470D0 (en) Therapeutic methods and materials
IL283335B (en) Dihydropyrimidine-2-one compounds and their medical use
HK1248697A1 (zh) 治療化合物及其用途
ZA201802256B (en) Compounds and therapeutic uses thereof
IL247325A0 (en) Therapeutic methods using noribogaine and related compounds
HK1232145A1 (zh) 雙功能化合物和用於降低尿酸水平的用途
IL252355A0 (en) Low dose a2a antagonist for the treatment of adhd and parkinson
GB201406172D0 (en) Therapy and pharmaceutical composition
IL248847A0 (en) Dosertalin dosage and method for treating adhd
GB201418541D0 (en) Materials for use with general hyperthermia treatment
GB201522994D0 (en) The combination of chinese medicine for treating ADHD
GB201501202D0 (en) Novel methods for diagnosis and therapy
GB201410387D0 (en) Compounds and their therapeutic use
GB201403496D0 (en) Compounds and their therapeutic use